ESX-5-targeted export of ESAT-6 in BCG combines enhanced immunogenicity & efficacy against murine tuberculosis with low virulence and reduced persistence-Reference-Cited by-同舟云学术

ESX-5-targeted export of ESAT-6 in BCG combines enhanced immunogenicity & efficacy against murine tuberculosis with low virulence and reduced persistence

Published:2021-12 Issue:50 Volume:39 Page:7265-7276
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Heijmenberg Isis^ORCID,Husain Aliabbas,Sathkumara Harindra D.^ORCID,Muruganandah Visai^ORCID,Seifert Julia^ORCID,Miranda-Hernandez Socorro,Kashyap Rajpal Singh,Field Matt A.^ORCID,Krishnamoorthy Gopinath^ORCID,Kupz Andreas^ORCID

Funder

NHMRC

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference57 articles.

1. WHO. Global Tuberculosis Report 2019; 2019. http://wwwwhoint/tb/publications/global_report/en/.

2. Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO's new end TB strategy. Lancet. 2015;385(9979):1799–801. Epub 2015/03/31. doi: 10.1016/s0140-6736(15)60570-0. PubMed PMID: 25814376.

3. Gengenbacher M, Nieuwenhuizen NE, Kaufmann S. BCG - old workhorse, new skills. Curr Opin Immunol. 2017;47:8–16. Epub 2017/07/19. doi: 10.1016/j.coi.2017.06.007. PubMed PMID: 28719821.

4. McShane H. Insights and challenges in tuberculosis vaccine development. The Lancet Respiratory medicine. 2019;7(9):810–9. Epub 2019/08/17. doi: 10.1016/s2213-2600(19)30274-7. PubMed PMID: 31416767.

5. Kaufmann SH, Lange C, Rao M, Balaji KN, Lotze M, Schito M, et al. Progress in tuberculosis vaccine development and host-directed therapies--a state of the art review. The Lancet Respiratory medicine. 2014;2(4):301–20. Epub 2014/04/11. doi: 10.1016/s2213-2600(14)70033-5. PubMed PMID: 24717627.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A second-generation recombinant BCG strain combines protection against murine tuberculosis with an enhanced safety profile in immunocompromised hosts;Vaccine;2024-10

2. Antigen identification strategies and preclinical evaluation models for advancing tuberculosis vaccine development;npj Vaccines;2024-03-09

3. The Immunogenicity and Safety of Mycobacterium tuberculosis-mosR-Based Double Deletion Strain in Mice;Microorganisms;2023-08-18

4. Impaired ESX‐3 Induces Bedaquiline Persistence in Mycobacterium abscessus Growing Under Iron‐Limited Conditions;Small Methods;2023-06-08

5. Repurposing mucosal delivery devices for live attenuated tuberculosis vaccines;Frontiers in Immunology;2023-03-30